Zest Health Announces $13M in Funding to Curb Unnecessary Pharmaceutical Spend through High-Touch Care
Portfolio Pulse from
Zest Health has secured $13 million in funding to address unnecessary pharmaceutical spending by focusing on high-touch care for inflammatory skin diseases. The company aims to reduce the overprescription of expensive biologics.
February 03, 2025 | 12:15 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Zest Health's new funding and focus on reducing overprescription of biologics could impact companies like Roivant Sciences (ROIV) involved in similar pharmaceutical sectors.
Zest Health's initiative to reduce the overprescription of expensive biologics could lead to decreased demand for such drugs, potentially affecting companies like Roivant Sciences that are involved in the development or sale of biologics.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50